期刊
FUTURE MEDICINAL CHEMISTRY
卷 14, 期 2, 页码 97-113出版社
Newlands Press Ltd
DOI: 10.4155/fmc-2021-0256
关键词
biphenyls; cancer immunotherapy; inhibitors; PD-1; PD-L1 interaction; small-molecule
资金
- Fujian Province Natural Science Foundation [2021J01309]
- Fundamental Research Funds for the Central Universities [ZQN-PY519]
Immune therapy targeting the PD-1/PD-L1 interaction with monoclonal antibodies has limitations, driving the exploration of small-molecule inhibitors as potential alternative therapeutic approaches.
Immunotherapy inhibiting the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) interaction has emerged as one of the most attractive cancer treatment strategies. So far, the clinically used PD-1/PD-L1 inhibitors are monoclonal antibodies, but monoclonal antibodies have several limitations, such as poor pharmacokinetic properties, unchecked immune responses and high production cost. The development of small-molecule inhibitors targeting PD-1/PD-L1 interaction is showing great promise as a potential alternative or complementary therapeutic approach of monoclonal antibodies. In this article, the authors classify the reported biphenyl small-molecule inhibitors into symmetrical and asymmetrical types based on their structural features and further review their representative inhibitors and biological activities, as well as the binding models for providing insight into further exploration of more potent biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据